Patent news from FiercePharma
NewsEU commissioner widens pharma probe
Europe's competition commissioner is casting a wide net in her pharma-market antitrust probe. After questioning some 100 companies--including Pfizer, GlaxoSmithKline, and Read more...
GSK accused of monopolizing Wellbutrin
Did GlaxoSmithKline try to monopolize the Wellbutrin market? A lawsuit now certified as class-action says so. The plaintiffs accuse GSK of artificially boosting Wellbutrin prices by fibbing to the Read more...
Drugmakers resist U.K. price goals
Drug companies are standing their ground in price negotiations with the U.K. government. Pharma is offering to cut the U.K.'s drug bill by roughly half the government's goal, The Daily Telegraph Read more...
Wyeth discounts Pristiq for big sales push
Think the latest-and-greatest drug would naturally be the most expensive? Think again. Now that its Pristiq antidepressant is Read more...
Neurontin fails bipolar med review
Review the research on epilepsy meds, and what do you find? Neurontin (gabapentin), is no better than placebo for bipolar disorder, according to the Prescribing for Better Outcomes center at the Read more...
Pfizer might be liable for generic Neurontin
You may pay the fine though you never collected the revenue. That's what a Philadelphia judge told Pfizer and Warner-Lambert last week in a trial over off-label marketing of Neurontin. If the Read more...
BBC: Reckitt schemed against generics
Reckitt Benckiser execs bragged in internal documents that they'd blocked generic competition for their Gaviscon stomach med for years--even after the drug went off patent. According to the BBC, The Read more...
Bayer loses Yasmin patent fight
Bayer had the Yasmin rug pulled out from under it yesterday. A U.S. court voided the contraceptive's key patent, leading the German conglomerate to revise its 2008 profit expectations Read more...
Teva abstains from Protonix fray
Teva Pharmaceuticals' dilemma: A rival generic drugmaker is ready Read more...
FDA shoots down Mevacor OTC
It's official: Merck's off-patent statin drug Mevacor can't go over-the-counter. About a month after Read more...
| Press ReleasesPRESS RELEASE: Teva Receives Favorable Court Decision Regarding Generic Famvir Tablets Teva Receives Favorable Court Decision Regarding Generic Famvir Tablets; Novartis’ Motion for Preliminary Injunction Denied JERUSALEM, Israel--Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) Read more... PRESS RELEASE: Forest Laboratories Announces Federal Appeals Court Upholds Lexapro Patent Decision Forest Laboratories Announces Federal Appeals Court Upholds Lexapro Patent Decision NEW YORK, Sept. 5 -- Forest Laboratories and H. Lundbeck A/S of Denmark said today that the U.S. Court of Appeals Read more... |
Get more Patent coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight